Scott A. Becka

526 total citations
20 papers, 412 citations indexed

About

Scott A. Becka is a scholar working on Molecular Medicine, Plant Science and Pharmacology. According to data from OpenAlex, Scott A. Becka has authored 20 papers receiving a total of 412 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Molecular Medicine, 9 papers in Plant Science and 8 papers in Pharmacology. Recurrent topics in Scott A. Becka's work include Antibiotic Resistance in Bacteria (20 papers), Plant Pathogenic Bacteria Studies (9 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). Scott A. Becka is often cited by papers focused on Antibiotic Resistance in Bacteria (20 papers), Plant Pathogenic Bacteria Studies (9 papers) and Antibiotics Pharmacokinetics and Efficacy (8 papers). Scott A. Becka collaborates with scholars based in United States, Japan and Pakistan. Scott A. Becka's co-authors include Krisztina M. Papp‐Wallace, Robert A. Bonomo, John J. LiPuma, Melissa D. Barnes, Magdalena A. Taracila, Christopher R. Bethel, Brigid Wilson, Barry N. Kreiswirth, Marisa Winkler and David van Duin and has published in prestigious journals such as Scientific Reports, Journal of Clinical Microbiology and The Journal of Infectious Diseases.

In The Last Decade

Scott A. Becka

20 papers receiving 407 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Scott A. Becka United States	11	331	157	141	70	62	20	412
Nazim Mustafa United Kingdom	10	321 1.0×	132 0.8×	68 0.5×	57 0.8×	90 1.5×	13	455
Concepción Segura Spain	10	442 1.3×	269 1.7×	183 1.3×	93 1.3×	93 1.5×	12	556
Mar Solé Spain	10	320 1.0×	75 0.5×	73 0.5×	75 1.1×	86 1.4×	10	445
Tsukasa Ito-Horiyama Japan	4	450 1.4×	362 2.3×	115 0.8×	146 2.1×	77 1.2×	6	518
Miki Takemura Japan	12	592 1.8×	432 2.8×	130 0.9×	204 2.9×	149 2.4×	34	707
Pablo A. Fraile-Ribot Spain	14	576 1.7×	348 2.2×	161 1.1×	206 2.9×	173 2.8×	32	671
Nikolaos A. Triarides United States	8	300 0.9×	182 1.2×	215 1.5×	60 0.9×	60 1.0×	9	484
Peter Staves United Kingdom	6	243 0.7×	126 0.8×	98 0.7×	98 1.4×	41 0.7×	7	331
Ester del Barrio-Tofiño Spain	7	523 1.6×	165 1.1×	80 0.6×	134 1.9×	270 4.4×	13	573
Jean-Marie Duez France	13	225 0.7×	116 0.7×	93 0.7×	29 0.4×	72 1.2×	25	400

Countries citing papers authored by Scott A. Becka

Since Specialization

Citations

This map shows the geographic impact of Scott A. Becka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott A. Becka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott A. Becka more than expected).

Fields of papers citing papers by Scott A. Becka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott A. Becka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott A. Becka. The network helps show where Scott A. Becka may publish in the future.

Co-authorship network of co-authors of Scott A. Becka

This figure shows the co-authorship network connecting the top 25 collaborators of Scott A. Becka. A scholar is included among the top collaborators of Scott A. Becka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Scott A. Becka. Scott A. Becka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mojica, María F., et al.. (2024). Cefepime-taniborbactam demonstrates potent in vitro activity vs Enterobacterales with bla _OXA-48. Microbiology Spectrum. 12(11). e0114424–e0114424. 1 indexed citations

Mojica, María F., Michiyoshi Nukaga, Scott A. Becka, et al.. (2024). Frameshift Mutations in Genes Encoding PBP3 and PBP4 Trigger an Unusual, Extreme β-Lactam Resistance Phenotype in Burkholderia multivorans. ACS Infectious Diseases. 10(11). 3810–3820. 1 indexed citations

Mojica, María F., Scott A. Becka, John J. LiPuma, et al.. (2023). Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States. Antimicrobial Agents and Chemotherapy. 67(11). e0049823–e0049823. 4 indexed citations

Becka, Scott A., et al.. (2022). The Class A β-Lactamase Produced by Burkholderia Species Compromises the Potency of Tebipenem against a Panel of Isolates from the United States. Antibiotics. 11(5). 674–674. 4 indexed citations

Tuttobene, Marisel R., Alejandro J. Vila, Parvin Shahrestani, et al.. (2021). Cerebrospinal fluid (CSF) augments metabolism and virulence expression factors in Acinetobacter baumannii. Scientific Reports. 11(1). 4737–4737. 30 indexed citations

Becka, Scott A., et al.. (2021). Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli. Antimicrobial Agents and Chemotherapy. 65(11). e0133221–e0133221. 18 indexed citations

Nukaga, Michiyoshi, et al.. (2021). Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from Burkholderia multivorans. ACS Infectious Diseases. 7(4). 826–837. 5 indexed citations

Papp‐Wallace, Krisztina M., Adam B. Shapiro, Scott A. Becka, et al.. (2020). In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species. Antimicrobial Agents and Chemotherapy. 65(3). 8 indexed citations

Becka, Scott A., et al.. (2019). “Switching Partners”: Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates. Journal of Clinical Microbiology. 57(8). 26 indexed citations

10.

Papp‐Wallace, Krisztina M., et al.. (2019). Structural Analysis of The OXA-48 Carbapenemase Bound to A “Poor” Carbapenem Substrate, Doripenem. Antibiotics. 8(3). 145–145. 10 indexed citations

11.

Becka, Scott A., et al.. (2019). Resurrecting Old β-Lactams: Potent Inhibitory Activity of Temocillin against Multidrug-ResistantBurkholderiaSpecies Isolates from the United States. Antimicrobial Agents and Chemotherapy. 63(4). 8 indexed citations

12.

Papp‐Wallace, Krisztina M., Scott A. Becka, Steven Park, et al.. (2019). Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa. The Journal of Infectious Diseases. 220(4). 666–676. 63 indexed citations

13.

Becka, Scott A., Steven H. Marshall, Kevin Nguyen, et al.. (2018). Sequence heterogeneity of the PenA carbapenemase in clinical isolates of Burkholderia multivorans. Diagnostic Microbiology and Infectious Disease. 92(3). 253–258. 11 indexed citations

14.

Barnes, Melissa D., Christopher R. Bethel, Scott A. Becka, et al.. (2018). Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam. Antimicrobial Agents and Chemotherapy. 62(5). 33 indexed citations

15.

Papp‐Wallace, Krisztina M., Melissa D. Barnes, Magdalena A. Taracila, et al.. (2018). Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy. 62(6). 82 indexed citations

16.

Becka, Scott A., Melissa D. Barnes, Magdalena A. Taracila, et al.. (2018). Characterization of the AmpC β-Lactamase from Burkholderia multivorans. Antimicrobial Agents and Chemotherapy. 62(10). 15 indexed citations

17.

Papp‐Wallace, Krisztina M., Scott A. Becka, Marisa Winkler, et al.. (2018). 2385. Ceftazidime–Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa. Open Forum Infectious Diseases. 5(suppl_1). S711–S711. 1 indexed citations

18.

Papp‐Wallace, Krisztina M., Scott A. Becka, María F. Mojica, et al.. (2017). Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients. ACS Infectious Diseases. 3(7). 502–511. 53 indexed citations

19.

Papp‐Wallace, Krisztina M., et al.. (2016). Exploring the Role of the Ω-Loop in the Evolution of Ceftazidime Resistance in the PenA β-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen. Antimicrobial Agents and Chemotherapy. 61(2). 15 indexed citations

20.

Papp‐Wallace, Krisztina M., Scott A. Becka, Magdalena A. Taracila, et al.. (2015). Exposing a β-Lactamase “Twist”: the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI β-Lactamase. Antimicrobial Agents and Chemotherapy. 60(2). 777–788. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact